Filing search / Kineta, Inc. / "Safety" / Page 4

CORRESP

y6ft9vq1e5gg

3 Oct 22

Correspondence with SEC

12:00am

UPLOAD

ihvcgot

26 Sep 22

Letter from SEC

12:00am

425

w0jxs9i6s lkjkpb37

23 Sep 22

Business combination disclosure

8:01am

8-K

EX-99.1

kvtqm8fqny67 n3nsuv

23 Sep 22

Regulation FD Disclosure

8:00am

425

eb1h5

20 Jul 22

Business combination disclosure

6:09am

8-K

EX-99.1

90wa4 vp5pb4

20 Jul 22

Regulation FD Disclosure

6:07am

425

tyefbq9w0kvo5

17 Jun 22

Business combination disclosure

4:03pm

8-K

EX-99.1

u1x7qfc

17 Jun 22

Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit

4:02pm

425

eetz3txt

6 Jun 22

Business combination disclosure

4:05pm